Duncan Bridgeman
|
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
February 20th Morning Report
SCL - Chief Financial Officer Transition
BLS - Strong YTD performance
CEN announces opening of NZ$75 million Retail Offer
AIA - 1H26 Interim Results
February 19th Morning Report
TWL - Share Purchase Plan Results
GMT revaluation, unit buyback and proposed structure update
Devon Funds Morning Note - 17 February 2026
CEN - Contact successfully completes NZ$450m Placement